Contribute Try STAT+ Today

The field of organs-on-chips scored an early victory Tuesday: Boston organ-on-a-chip startup Emulate has partnered with the Food and Drug Administration to test whether the technology works for toxicity screening purposes.

But this is just an early gambit into the wider world of organs-on-chips — since tox screening accounts for just 10 percent of the preclinical testing typically conducted on animals, said Dr. Thomas Hartung, who is director of the Center for Alternatives to Animal Testing at Johns Hopkins University.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Complete metabolic profile and other laboratory test in real-time not drawing blood or urine through the integment…

Comments are closed.